Do analysts rate LABT or BON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, LABT or BON?

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Bon Natural Life. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A N/A N/A N/A Bon Natural Life $18.67M 0.52 -$2M N/A N/A

Is LABT or BON more profitable?

Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A Bon Natural Life N/A N/A N/A

Which has higher earnings & valuation, LABT or EGRX?

Eagle Pharmaceuticals has higher revenue and earnings than Lakewood-Amedex Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A N/A N/A N/A Eagle Pharmaceuticals $257.55M 0.03 $35.64M $1.18 0.57

Is LABT or EGRX more profitable?

Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A Eagle Pharmaceuticals N/A N/A N/A

Do analysts rate LABT or ERNA?

Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 412.38%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, LABT or ERNA?

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A N/A N/A N/A Ernexa Therapeutics $580K 11.81 -$14.08M -$26.20 N/A

Is LABT or ERNA more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A Ernexa Therapeutics N/A -263.74% -151.16%

Do analysts rate TRAW or LABT?

Traws Pharma presently has a consensus target price of $1.00, indicating a potential upside of 43.27%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Traws Pharma is more favorable than Lakewood-Amedex Biotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Lakewood-Amedex Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, TRAW or LABT?

Traws Pharma has higher revenue and earnings than Lakewood-Amedex Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Traws Pharma $2.79M 2.54 $9.17M -$1.69 N/A Lakewood-Amedex Biotherapeutics N/A N/A N/A N/A N/A

Is TRAW or LABT more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -913.18% -133.88% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Does the media favor TRAW or LABT?

In the previous week, Traws Pharma and Traws Pharma both had 1 articles in the media. Traws Pharma's average media sentiment score of 0.00 equaled Lakewood-Amedex Biotherapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lakewood-Amedex Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer LABT or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, LABT or ASBP?

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Aspire Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A N/A N/A N/A Aspire Biopharma $10K 737.10 -$24.48M -$116.67 N/A

Is LABT or ASBP more profitable?

Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A Aspire Biopharma N/A N/A -398.04%

Lakewood-Amedex Biotherapeutics (LABT) Competitors

$2.27 -0.12 (-4.85%)

As of 01:37 PM Eastern

Compare

LABT vs. BON, EGRX, ERNA, TRAW, and ASBP

Should you buy Lakewood-Amedex Biotherapeutics stock or one of its competitors? MarketBeat compares Lakewood-Amedex Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lakewood-Amedex Biotherapeutics include Bon Natural Life (BON), Eagle Pharmaceuticals (EGRX), Ernexa Therapeutics (ERNA), Traws Pharma (TRAW), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry.

How does Lakewood-Amedex Biotherapeutics compare to Bon Natural Life?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Bon Natural Life	N/A	N/A	N/A

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Bon Natural Life.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Bon Natural Life	$18.67M	0.52	-$2M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Bon Natural Life. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score.

Company	Overall Sentiment
Lakewood-Amedex Biotherapeutics	Neutral
Bon Natural Life	Neutral

0.6% of Bon Natural Life shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bon Natural Life beats Lakewood-Amedex Biotherapeutics on 4 of the 5 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Eagle Pharmaceuticals?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Eagle Pharmaceuticals has higher revenue and earnings than Lakewood-Amedex Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.57

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Eagle Pharmaceuticals	N/A	N/A	N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Eagle Pharmaceuticals. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Lakewood-Amedex Biotherapeutics	Neutral
Eagle Pharmaceuticals	Neutral

Summary

Eagle Pharmaceuticals beats Lakewood-Amedex Biotherapeutics on 3 of the 4 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Ernexa Therapeutics?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Ernexa Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Ernexa Therapeutics	$580K	11.81	-$14.08M	-$26.20	N/A

70.6% of Ernexa Therapeutics shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Ernexa Therapeutics	N/A	-263.74%	-151.16%

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Lakewood-Amedex Biotherapeutics. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 1 mentions for Lakewood-Amedex Biotherapeutics. Ernexa Therapeutics' average media sentiment score of 0.25 beat Lakewood-Amedex Biotherapeutics' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakewood-Amedex Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ernexa Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 412.38%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Ernexa Therapeutics beats Lakewood-Amedex Biotherapeutics on 8 of the 10 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Traws Pharma has higher revenue and earnings than Lakewood-Amedex Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	2.54	$9.17M	-$1.69	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Traws Pharma presently has a consensus target price of $1.00, indicating a potential upside of 43.27%. Given Traws Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Traws Pharma is more favorable than Lakewood-Amedex Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Lakewood-Amedex Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

8.0% of Traws Pharma shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Traws Pharma and Traws Pharma both had 1 articles in the media. Traws Pharma's average media sentiment score of 0.00 equaled Lakewood-Amedex Biotherapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakewood-Amedex Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Traws Pharma beats Lakewood-Amedex Biotherapeutics on 5 of the 7 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Aspire Biopharma?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Aspire Biopharma	N/A	N/A	-398.04%

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Aspire Biopharma. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Aspire Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Lakewood-Amedex Biotherapeutics	Neutral
Aspire Biopharma	Neutral

19.2% of Aspire Biopharma shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Aspire Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Aspire Biopharma	$10K	737.10	-$24.48M	-$116.67	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Aspire Biopharma beats Lakewood-Amedex Biotherapeutics on 4 of the 6 factors compared between the two stocks.

Get Lakewood-Amedex Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LABT vs. The Competition

Export

Metric	Lakewood-Amedex Biotherapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.98M	$956.28M	$4.40B	$12.41B
Dividend Yield	N/A	4.84%	16.13%	6.49%
P/E Ratio	N/A	1.60	23.82	24.26
Price / Sales	N/A	116.42	153.09	116.57
Price / Cash	N/A	20.06	34.70	57.41
Price / Book	N/A	8.37	14.12	6.38
Net Income	N/A	-$4.99M	$116.30M	$331.53M
7 Day Performance	-31.09%	-1.72%	-2.03%	-1.95%
1 Month Performance	-64.49%	2.94%	-1.07%	0.77%
1 Year Performance	N/A	48.92%	9.15%	21.85%

Lakewood-Amedex Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LABT Lakewood-Amedex Biotherapeutics	N/A	$2.27 -4.9%	N/A	N/A	$3.98M	N/A	N/A	5	News Coverage
BON Bon Natural Life	0.885 of 5 stars	$1.13 -2.6%	N/A	-16.4%	$9.43M	$18.67M	N/A	100	Positive News Gap Down
EGRX Eagle Pharmaceuticals	N/A	$0.67 +11.7%	N/A	N/A	$8.70M	$257.55M	0.57	100
ERNA Ernexa Therapeutics	3.7036 of 5 stars	$6.97 -5.8%	$30.00 +330.4%	-86.4%	$8.63M	$580K	N/A	10	Gap Down
TRAW Traws Pharma	3.3741 of 5 stars	$0.83 -0.6%	$1.00 +20.9%	-51.9%	$8.45M	$2.79M	N/A	17

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LABT) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakewood-Amedex Biotherapeutics (LABT) Competitors

LABT vs. BON, EGRX, ERNA, TRAW, and ASBP

How does Lakewood-Amedex Biotherapeutics compare to Bon Natural Life?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Eagle Pharmaceuticals?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Ernexa Therapeutics?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Traws Pharma?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Aspire Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LABT vs. The Competition

Lakewood-Amedex Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakewood-Amedex Biotherapeutics (LABT) Competitors

LABT vs. BON, EGRX, ERNA, TRAW, and ASBP

How does Lakewood-Amedex Biotherapeutics compare to Bon Natural Life?

Is LABT or BON more profitable?

Which has better earnings & valuation, LABT or BON?

Do analysts rate LABT or BON?

Does the media favor LABT or BON?

Do insiders and institutionals have more ownership in LABT or BON?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Eagle Pharmaceuticals?

Do insiders & institutionals have more ownership in LABT or EGRX?

Which has higher earnings & valuation, LABT or EGRX?

Is LABT or EGRX more profitable?

Does the media prefer LABT or EGRX?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Ernexa Therapeutics?

Which has better earnings & valuation, LABT or ERNA?

Do institutionals & insiders believe in LABT or ERNA?

Is LABT or ERNA more profitable?

Does the media prefer LABT or ERNA?

Do analysts rate LABT or ERNA?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Traws Pharma?

Which has better earnings & valuation, TRAW or LABT?

Do analysts rate TRAW or LABT?

Is TRAW or LABT more profitable?

Do institutionals and insiders hold more shares of TRAW or LABT?

Does the media favor TRAW or LABT?

Summary

How does Lakewood-Amedex Biotherapeutics compare to Aspire Biopharma?

Is LABT or ASBP more profitable?

Does the media prefer LABT or ASBP?

Do insiders & institutionals have more ownership in LABT or ASBP?

Which has preferable earnings and valuation, LABT or ASBP?

Do analysts prefer LABT or ASBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LABT vs. The Competition

Lakewood-Amedex Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools